Related Experiment Video
Updated: Mar 16, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
New Molecular Targets of Anticancer Therapy - Current Status and Perspectives
Marianna Zajac, Izabela Muszalska, Anna Jelinska1
1Department of Pharmaceutical Chemistry, Grunwaldzka Str. 6, 60-780 Poznan, Poland.
Abstract:
Molecularly targeted anticancer therapy involves the use of drugs or other substances affecting specific molecular targets that play a part in the development, progression and spread of a given neoplasm. By contrast, the majority of classical chemotherapeutics act on all rapidly proliferating cells, both healthy and cancerous ones. Target anticancer drugs are designed to achieve a particular aim and they usually act cytostatically, not cytotoxically like classical chemotherapeutics. At present, more than 300 biological molecular targets have been identified. The proteins involved in cellular metabolism include (among others) receptor proteins, signal transduction proteins, mRNA thread matrix synthesis proteins participating in neoplastic transformation, cell cycle control proteins, functional and structural proteins. The receptor proteins that are targeted by currently used anticancer drugs comprise the epithelial growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor(VEGFR). Target anticancer drugs may affect extracellular receptor domains (antibodies) or intracellular receptor domains (tyrosine kinase inhibitors). The blocking of the mRNA thread containing information about the structure of oncogenes (signal transduction proteins) is another molecular target of anticancer drugs. That type of treatment, referred to as antisense therapy, is in clinical trials. When the synthesis of genetic material is disturbed, in most cases the passage to the next cycle phase is blocked. The key proteins responsible for the blockage are cyclines and cycline- dependent kinases (CDK). Clinical trials are focused on natural and synthetic substances capable of blocking various CDKs. The paper discusses the molecular targets and chemical structure of target anticancer drugs that have been approved for and currently applied in antineoplastic therapy together with indications and contraindications for their application.
Insights
Molecularly targeted cancer therapy offers a precise approach by targeting specific molecules involved in cancer growth, unlike traditional chemotherapy. This review details approved targeted drugs, their molecular targets, and clinical applications.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Classical chemotherapy affects all rapidly proliferating cells, both healthy and cancerous.
- Molecularly targeted anticancer therapy utilizes drugs that specifically inhibit molecular targets driving cancer development, progression, and spread.
- Over 300 molecular targets have been identified, including receptor proteins, signal transduction proteins, and cell cycle control proteins.
Purpose of the Study:
- To review molecular targets and chemical structures of approved targeted anticancer drugs.
- To discuss the indications and contraindications for these targeted therapies.
- To differentiate targeted therapy from classical chemotherapeutics.
Main Methods:
- Review of approved molecularly targeted anticancer drugs.
- Analysis of drug mechanisms targeting specific proteins like EGFR, PDGFR, VEGFR, and CDKs.
- Discussion of antisense therapy and CDK inhibitors in clinical trials.
Main Results:
- Identified key molecular targets including receptor tyrosine kinases (EGFR, PDGFR, VEGFR) and cell cycle regulators (cyclins, CDKs).
- Described drug classes such as antibodies and tyrosine kinase inhibitors targeting extracellular and intracellular domains.
- Highlighted emerging therapies like antisense therapy and CDK inhibitors currently in clinical trials.
Conclusions:
- Molecularly targeted therapy provides a more precise, often cytostatic, approach to cancer treatment compared to cytotoxic chemotherapy.
- Understanding specific molecular targets is crucial for developing effective and individualized anticancer strategies.
- Ongoing research into novel targets and therapies like antisense and CDK inhibitors promises further advancements in oncology.
More Related Videos
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Cancer